A Phase 2 interventional study of CHF 5259 12.5 µg + Qvar and CHF 5259 placebo + Qvar in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 28 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing glycopyrrolate in Asthma — 1 open to participants now, 1 under way, none of them phase 3. Glycopyrrolate · Asthma.
Among the 10 studies testing glycopyrrolate in Asthma, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 2nd registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →1 of the 10 studies testing glycopyrrolate in Asthma is open now, in 8 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Bulgaria, Colombia, Guatemala and 5 more countries
Ages 6–11
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 4 · Phase 4 2
First in 2014; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 69 across the 10 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
81 studies in Asthma by Chiesi Farmaceutici S.p.A.: 11 open now, 11 under way, 2 of them phase 3. Of 69 finished, 13 (19%) have results posted.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 33rd largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2014, is one of 25 in phase 2, and was the 41st registered.
Chiesi Farmaceutici S.p.A.’s Asthma studies by the year they started, since 2002.
1 of the studies testing glycopyrrolate in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05222529Novartis PharmaceuticalsPharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma | 2027-07-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing glycopyrrolate in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 81 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary objective
The primary objective was to evaluate the superiority of CHF 5259 (glycopyrronium bromide [GB]) in a pressurised metered dose inhaler (pMDI) (50 μg total daily dose) versus placebo in terms of forced expiratory volume in the first second (FEV1) area under the curve between time 0 and 12 hours (AUC0-12h) normalised by time on Day 42.
Key secondary objective
The key secondary objective was to evaluate the superiority of CHF 5259 pMDI (50 μg total daily dose) versus placebo in terms of peak FEV1 on Day 42.
Secondary objectives
The secondary objectives were:
This was a phase IIb, multicentre, randomised, double-blind, placebo-controlled, 2-way crossover study consisting of two 6-week treatment periods (42 days each ±2 days), separated by a 1-week washout period (+2 days). The study employed a complete block design and a multiple-dosing regimen. It was designed as an add-on therapy to evaluate the efficacy and safety of CHF 5259 pMDI when used in combination with Qvar® pMDI in patients with uncontrolled asthma on low-to-medium doses of inhaled corticosteroids (ICS).
The crossover design was chosen because each patient serves as their own control, thereby reducing variability caused by inter-patient differences and minimizing the effects of potential confounding factors. This design improve statistical power, allowing for estimation of comparisons between treatments with a smaller sample size compared to a parallel arms study. The study aimed to randomise 98 patients to ensure at least 68 evaluable participants, accounting for an estimated 30% dropout or non-evaluable rate.
The study included the following phases:
Comprised two treatment periods:
During these periods, patients received two puffs of their assigned treatment (CHF 5259 or placebo) twice daily (morning and evening), in addition to their stable Qvar® therapy.
A 1-week washout period (+2 days) was implemented between the two treatment periods to minimize the potential for carryover effects from the first treatment period.
Overall, the study lasted 17 weeks per participant, including a 1-week pre-screening period; the 2-week run-in period; two 6-week treatment periods, and the follow-up phase. The two 6-week treatment periods allowed sufficient time for the evaluation of efficacy endpoints, while the 1-week washout period was deemed adequate to eliminate residual treatment effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of ) unless are using at least one or more of the following reliable methods of :
Any women (physiologic menopause defined as "12 consecutive months of amenorrhea") or women permanently sterilised (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) were enrolled in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this sequence, patients received: CHF 5259 pMDI (Active Treatment): CHF 5259 pMDI 12.5 µg as two puffs twice daily (b.i.d.), for a total daily dose of 50 µg, administered via metered dose inhalation of pressurised solution using a standard actuator. Treatment duration: 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg. Wash-Out Period (1 Week): Qvar® pMDI 50 µg or 100 µg b.i.d., administered via metered dose inhalation of pressurised solution, with a daily dose ranging from 100 µg to 400 µg. Placebo of CHF 5259 pMDI (Control Treatment): A matched placebo for CHF 5259 pMDI, administered via metered dose inhalation of pressurised solution using a standard actuator. Treatment duration: 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg.
Drug: CHF 5259 12.5 µg + Qvar · Drug: CHF 5259 placebo + Qvar
In this sequence, patients received: Placebo of CHF 5259 pMDI (Control Treatment): A matched placebo for CHF 5259 pMDI, administered via metered dose inhalation using a standard actuator for 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg. Wash-Out Period (1 Week): Qvar® pMDI 50 µg or 100 µg b.i.d., administered via metered dose inhalation using a standard actuator, with a daily dose ranging from 100 µg to 400 µg. CHF 5259 pMDI (Active Treatment): CHF 5259 pMDI 12.5 µg as two puffs twice daily (b.i.d.), for a total daily dose of 50 µg, administered via metered dose inhalation using a standard actuator for 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg.
Drug: CHF 5259 12.5 µg + Qvar · Drug: CHF 5259 placebo + Qvar
Drug page: Glycopyrrolate
comparison of CHF 5259 versus placebo over 2 treatment periods of 6 weeks ± 2 days
Also known as: glycopyrrolate bromide
comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks ± 2 days
Also known as: Placebo
FEV1 AUC0-12h Normalized by Time on Day 42 (ITT Population)
FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.
Time frame: Day 42
FEV1 AUC0-12h Normalized by Time on Day 42 (PP Population)
FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.
Time frame: Day 42
Change From Baseline in Peak FEV1 on Day 42 (ITT Population)
The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.
Time frame: Baseline and Day 42
Change From Baseline in Peak FEV1 on Day 42 (PP Population)
The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.
Time frame: Baseline and Day 42
FEV1 AUC0-12h Normalized by Time on Day 1
FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose on Day 1 post-dose.
Time frame: Day 1
FEV1 AUC0-3h Normalised by Time on Day 1
AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was assessed at 15 min, 30 min, 45 min, 1h, 2h, 3h on day 1.
Time frame: Day 1
FEV1 AUC0-3h Normalised by Time on Day 42
AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h. on day 1 and on day 42
Time frame: Day 42
Change From Baseline in Peak FEV1 on Day 1
The peak FEV1 is determined as the maximum FEV1 value obtained between 15 minutes and 12 hours post-dose. The baseline value is the mean of the pre-dose measurement of FEV1 at Day 1 of each treatment period.
Time frame: Baseline and Day 1
Change From Baseline in Pre-dose Morning Through FEV1 on Day 42
The pre-dose morning FEV1 is defined as the mean of the two measurements at 45 and 15 minutes predose.
Time frame: Baseline and Day 42
Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 1
Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.
Time frame: Baseline and Day 1
Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 42
Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.
Time frame: Baseline and Day 42
Average Daily PEF (Morning and Evening) During Treatment Periods
PEF = Peak Expiratory Flow. PEF was measured at home by patients using a portable e-peak flow meter (AM3 device). Patients were educated on the purpose and technique of PEF home monitoring and specific instructions for use were made available to them. During the run-in/wash-out and the two treatment periods (from V1 to V5), PEF was monitored twice daily, in the morning and in the evening, before the intake of the background medication or study medication. PEF was also assessed during the visits only for information purpose of the Investigator. During each measurement session, the patient performed 3 blows and data were recorded in the device. The average daily morning PEF is the mean value of all morning PEF measurements. The average daily evening PEF is the mean value of all evening PEF measurements. Please note: the average daily morning PEF and the average daily evening PEF during the treatment periods are reported.
Time frame: Twice Daily during treatment periods (from V1 to V5)
Average Daily Asthma Symptoms (Daytime) During Treatment Periods
Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Daytime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom 1. = Mild: aware of symptoms which can be easily tolerated 2. = Moderate: discomfort causing interference with daily activity 3. = Severe: inability to work/make usual activity The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score daytime = Σ〖Cough daytime score + Wheeze daytime score + Chest Tightness daytime score * Breathlessness daytime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.
Time frame: During treatment periods (from V2 to V5), up to 6 weeks
Average Daily Asthma Symptoms (Nighttime) During Treatment Periods
Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Nighttime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom 1. = Mild: symptoms not causing awakening 2. = Moderate: discomfort causing awakenings 3. = Severe: causing awakenings for most of the night / don't allow to sleep at all The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score nighttime = Σ〖Cough nighttime score + Wheeze nighttime score + Chest Tightness nighttime score + Breathlessness nighttime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.
Time frame: Daily during treatment periods (from V2 to V5)
Percentage of Asthma Control Days During the Treatment Periods
An asthma control day is derived from patient diary data, and is defined as days on which the patient meets both of the following criteria: a total asthma symptom score (daytime + nighttime) of 0, indicating no symptoms such as cough, wheeze, chest tightness, or breathlessness, and no use of rescue medication during the day.The percentage of control days is calculated as the number of asthma control days / number of days with available data.
Time frame: During the treatment periods (from V2 to V5)
Average Use of Rescue Medication (Number of Puffs/Day)
The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the first parameter is reported.
Time frame: During the treatment periods (from V2 to V5)
Average Use of Rescue Medication (Number of Times/Day)
The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the second parameter is reported.
Time frame: During the treatment periods (from V2 to V5)
Change From Baseline in Asthma Control Questionnaire (ACQ) Total Score on Day 42
The ACQ is a validated questionnaire rating patient asthma control. It has a multidimensional construct assessing symptoms (5 questions-self-administered) and rescue bronchodilator use (1 question-self-administered), and FEV1% predicted (1 question answered by clinicians). For each of the 7 questions, possible answer could score from 0 (no impairment for symptoms and rescue use) to 6 (maximum impairment for symptoms and rescue use). The questions are equally weighted and the ACQ total score is the mean of the 7 questions and therefore between 0 (asthma totally controlled) and 6 (asthma severely uncontrolled).
Time frame: Baseline and Day 42
Change From Baseline in FVC on Day 1
FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.
Time frame: Baseline and Day 1
Change From Baseline in FVC on Day 42
FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.
Time frame: Baseline and Day 42
A total of 138 patients were screened, with 98 patients randomised to one of the following two treatment sequence groups: * CHF 5259 pMDI - placebo: n = 50 * Placebo - CHF 5259 pMDI: n = 48
| Milestone | CHF5259 pMDI - Placebo pMDI Sequence | Placebo pMDI - CHF 5259 pMDI |
|---|---|---|
| Started | 50 | 48 |
| Completed | 50 | 47 |
| Not completed | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.
| liters | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| FEV1 AUC0-12h Normalized by Time on Day 42 (ITT Population) | 2.470 ± 0.857 | 2.373 ± 0.830 |
FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.
| liters | CHF5259 pMDI | Placebo pMDI |
|---|---|---|
| FEV1 AUC0-12h Normalized by Time on Day 42 (PP Population) | 2.480 ± 0.849 | 2.365 ± 0.827 |
The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.
| liters | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Change From Baseline in Peak FEV1 on Day 42 (ITT Population) | 0.394 ± 0.281 | 0.278 ± 0.293 |
The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.
| liters | CHF5259 pMDI | Placebo pMDI |
|---|---|---|
| Change From Baseline in Peak FEV1 on Day 42 (PP Population) | 0.392 ± 0.263 | 0.258 ± 0.299 |
FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose on Day 1 post-dose.
| liters | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| FEV1 AUC0-12h Normalized by Time on Day 1 | 2.482 ± 0.862 | 2.356 ± 0.835 |
AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was assessed at 15 min, 30 min, 45 min, 1h, 2h, 3h on day 1.
| liters | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| FEV1 AUC0-3h Normalised by Time on Day 1 | 2.496 ± 0.863 | 2.344 ± 0.815 |
AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h. on day 1 and on day 42
| liters | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| FEV1 AUC0-3h Normalised by Time on Day 42 | 2.498 ± 0.870 | 2.357 ± 0.839 |
The peak FEV1 is determined as the maximum FEV1 value obtained between 15 minutes and 12 hours post-dose. The baseline value is the mean of the pre-dose measurement of FEV1 at Day 1 of each treatment period.
| liters | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Change From Baseline in Peak FEV1 on Day 1 | 0.384 ± 0.248 | 0.286 ± 0.237 |
The pre-dose morning FEV1 is defined as the mean of the two measurements at 45 and 15 minutes predose.
| liters | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Change From Baseline in Pre-dose Morning Through FEV1 on Day 42 | 0.136 ± 0.291 | 0.041 ± 0.258 |
Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.
| percentage of predicted FEV1 | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 1 | 5.1 ± 8.1 | 2.9 ± 7.5 |
Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.
| percentage of predicted normal value | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 42 | 5.8 ± 8.9 | 2.9 ± 8.5 |
PEF = Peak Expiratory Flow. PEF was measured at home by patients using a portable e-peak flow meter (AM3 device). Patients were educated on the purpose and technique of PEF home monitoring and specific instructions for use were made available to them. During the run-in/wash-out and the two treatment periods (from V1 to V5), PEF was monitored twice daily, in the morning and in the evening, before the intake of the background medication or study medication. PEF was also assessed during the visits only for information purpose of the Investigator. During each measurement session, the patient performed 3 blows and data were recorded in the device. The average daily morning PEF is the mean value of all morning PEF measurements. The average daily evening PEF is the mean value of all evening PEF measurements. Please note: the average daily morning PEF and the average daily evening PEF during the treatment periods are reported.
| liters/min | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| average daily morning | 363.2 ± 117.7 | 346.9 ± 111.5 |
| average daily evening | 372.4 ± 117 | 355.5 ± 110.5 |
Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Daytime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom 1. = Mild: aware of symptoms which can be easily tolerated 2. = Moderate: discomfort causing interference with daily activity 3. = Severe: inability to work/make usual activity The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score daytime = Σ〖Cough daytime score + Wheeze daytime score + Chest Tightness daytime score * Breathlessness daytime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.
| score on a scale | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Average Daily Asthma Symptoms (Daytime) During Treatment Periods | 2.62 ± 1.98 | 2.66 ± 1.84 |
Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Nighttime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom 1. = Mild: symptoms not causing awakening 2. = Moderate: discomfort causing awakenings 3. = Severe: causing awakenings for most of the night / don't allow to sleep at all The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score nighttime = Σ〖Cough nighttime score + Wheeze nighttime score + Chest Tightness nighttime score + Breathlessness nighttime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.
| score on a scale | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Average Daily Asthma Symptoms (Nighttime) During Treatment Periods | 2.35 ± 2.1 | 2.39 ± 2.0 |
An asthma control day is derived from patient diary data, and is defined as days on which the patient meets both of the following criteria: a total asthma symptom score (daytime + nighttime) of 0, indicating no symptoms such as cough, wheeze, chest tightness, or breathlessness, and no use of rescue medication during the day.The percentage of control days is calculated as the number of asthma control days / number of days with available data.
| percentage of days | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Percentage of Asthma Control Days During the Treatment Periods | 21.7 ± 32.3 | 19.4 ± 28.5 |
The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the first parameter is reported.
| number of puffs/day | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Average Use of Rescue Medication (Number of Puffs/Day) | 1 ± 1.6 | 1.1 ± 1.5 |
The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the second parameter is reported.
| number of times/day | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Average Use of Rescue Medication (Number of Times/Day) | 0.8 ± 1.4 | 0.9 ± 1.3 |
The ACQ is a validated questionnaire rating patient asthma control. It has a multidimensional construct assessing symptoms (5 questions-self-administered) and rescue bronchodilator use (1 question-self-administered), and FEV1% predicted (1 question answered by clinicians). For each of the 7 questions, possible answer could score from 0 (no impairment for symptoms and rescue use) to 6 (maximum impairment for symptoms and rescue use). The questions are equally weighted and the ACQ total score is the mean of the 7 questions and therefore between 0 (asthma totally controlled) and 6 (asthma severely uncontrolled).
| score on a scale | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire (ACQ) Total Score on Day 42 | -0.39 ± 0.59 | -0.17 ± 0.56 |
FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.
| liters | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Change From Baseline in FVC on Day 1 | 0.105 ± 0.348 | 0.114 ± 0.319 |
FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.
| liters | CHF5259 pMDI - ITT | Placebo pMDI - ITT |
|---|---|---|
| Change From Baseline in FVC on Day 42 | 0.096 ± 0.34 | 0.068 ± 0.346 |
Collected over AEs were collected from screening (Visit 1, D-14) to follow-up (Visit 6, week 14), or, in case, at early termination (EOT). Please note that AEs and overall mortality presented hereunder represent the safety set (i.e. all patients receiving any amount of study drug, including both run-in and randomized patients). As per planned analysis, AEs were collected in a combined manner: i.e. data on the run-in phase were combined with the ones of the reported arms.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in and Randomized CHF5259 pMDI (Safety Population) | 0/97 (0%) | 0/97 (0%) | 13/97 (13.4%) |
| Run-in and Randomized Placebo pMDI (Safety Population) | 0/98 (0%) | 0/98 (0%) | 11/98 (11.2%) |
| Event | Run-in and Randomized CHF5259 pMDI (Safety Population) | Run-in and Randomized Placebo pMDI (Safety Population) |
|---|---|---|
| NasopharyngitisInfections and infestations | 4/97 | 3/98 |
| Weight increasedInvestigations | 2/97 | 0/98 |
| InfluenzaInfections and infestations | 1/97 | 0/98 |
| PeriodontitisInfections and infestations | 1/97 | 0/98 |
| Skin bacterial infectionInfections and infestations | 1/97 | 0/98 |
| Blood pressure increasedInvestigations | 1/97 | 0/98 |
| Hepatic steatosisHepatobiliary disorders | 1/97 | 1/98 |
| NeuritisNervous system disorders | 1/97 | 0/98 |
| Sinus tachycardiaCardiac disorders | 1/97 | 0/98 |
| Eye irritationEye disorders | 1/97 | 0/98 |
ITT population: All randomised patients who received at least one dose of the study medication and with at least one available evaluation of efficacy after the baseline were included in the ITT population. Above demographics, all the efficacy variables were analysed based on the ITT population.
| Age, Categorical(Participants) | Sequence CHF 5259 pMDI - Placebo pMDI + Qvar | Sequence Placebo pMDI - CHF 5259 pMDI + Qvar | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 45 | 44 | 89 |
| >=65 years | 5 | 4 | 9 |
| Age, Continuous(years) | Sequence CHF 5259 pMDI - Placebo pMDI + Qvar | Sequence Placebo pMDI - CHF 5259 pMDI + Qvar | Total |
|---|---|---|---|
| Mean | 48.8 ± 14.0 | 47.2 ± 12.8 | 48.0 ± 13.4 |
| Sex: Female, Male(Participants) | Sequence CHF 5259 pMDI - Placebo pMDI + Qvar | Sequence Placebo pMDI - CHF 5259 pMDI + Qvar | Total |
|---|---|---|---|
| Female | 30 | 31 | 61 |
| Male | 20 | 17 | 37 |
| Region of Enrollment(participants) | Sequence CHF 5259 pMDI - Placebo pMDI + Qvar | Sequence Placebo pMDI - CHF 5259 pMDI + Qvar | Total |
|---|---|---|---|
| Netherlands | 0 | 1 | 1 |
| Poland | 17 | 19 | 36 |
| Italy | 1 | 1 | 2 |
| Bulgaria | 18 | 19 | 37 |
| Germany | 14 | 8 | 22 |
Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
Data sharing details ↗ · www.chiesi.com
Ran from Nov 2014 to primary completion in Aug 2015, 8 months.
Results were first posted in Apr 2026, 10 years 8 months after primary completion.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 8 months is below that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate